Skip to main content
Back
SUPN logo

Supernus Pharmaceuticals, Inc.

Data quality: 100%
SUPN
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$49.25
▲ $1.49 (3.12%)
Mkt Cap: 2.84B
Day Range
$47.75 $49.34
52-Week Range
$29.16 $59.68
Volume
558,737
50D / 200D Avg
$51.14 / $45.13
Prev Close
$47.76

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -73.6 0.4
P/B 0.0 2.9
ROE % 0.0 3.7
Net Margin % -5.4 3.8
Rev Growth 5Y % 5.5 10.0
D/E 0.0 0.2

Key Takeaways

Revenue grew 5.53% annually over 5 years — modest growth
Earnings declined -152.19% over the past year
Debt/Equity of 0.03 — conservative balance sheet
Generating 45.99M in free cash flow
PEG of 0.48 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3.10%

Growth

Revenue Growth (5Y)
5.53%
Revenue (1Y)8.63%
Earnings (1Y)-152.19%
FCF Growth (3Y)-35.49%

Quality

Return on Equity
-0.01%
ROIC0.00%
Net Margin-5.36%
Op. Margin-5.13%

Safety

Debt / Equity
0.03
Current Ratio1.90
Interest Coverage0.00

Valuation

P/E Ratio
-73.56
P/B Ratio0.00
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 8.63% Revenue Growth (3Y) 8.79%
Earnings Growth (1Y) -152.19% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 5.53% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 718.95M Net Income (TTM) -38.55M
ROE -0.01% ROA 0.00%
Gross Margin 89.63% Operating Margin -5.13%
Net Margin -5.36% Free Cash Flow (TTM) 45.99M
ROIC 0.00% FCF Growth (3Y) -35.49%
Safety
Debt / Equity 0.03 Current Ratio 1.90
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -73.56 P/B Ratio 0.00
P/S Ratio 3.94 PEG Ratio 0.48
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 2.84B Enterprise Value -95.25B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 718.95M 661.82M 607.52M 667.24M 579.78M
Net Income -38.55M 73.87M 1.32M 60.71M 53.42M
EPS (Diluted) -0.68 1.32 0.02 1.04 0.98
Gross Profit 644.39M 583.91M 523.74M 580.02M 504.71M
Operating Income -36.86M 81.67M -5.27M 46.12M 86.03M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.45T 1.37B 1.28B 1.70B 1.69B
Total Liabilities 390.93B 332.34M 356.16M 816.30M 873.30M
Shareholders' Equity 1.06T 1.04B 921.52M 886.20M 815.85M
Total Debt 30.37B 34.27M 41.53M 444.76M 427.03M
Cash & Equivalents 128.45B 69.33M 75.05M 93.12M 203.43M
Current Assets 644.18B 686.07M 493.11M 734.15M 601.59M
Current Liabilities 338.17B 292.40M 290.20M 687.96M 315.38M

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#810 of 820
4

Recent Activity

Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026